Transcode Therapeutics Inc banner

Transcode Therapeutics Inc
NASDAQ:RNAZ

Watchlist Manager
Transcode Therapeutics Inc Logo
Transcode Therapeutics Inc
NASDAQ:RNAZ
Watchlist
Price: 5.69 USD 3.27% Market Closed
Market Cap: $5.4m

Intrinsic Value

RNAZ doesn't have a meaningful market cap.

The intrinsic value for Transcode Therapeutics Inc (RNAZ) under the Base Case is 2.56 USD. Compared with the current market price of 5.69 USD, the stock appears Overvalued by 55% .

RNAZ Intrinsic Value
2.56 USD
Overvaluation 55%
Intrinsic Value
Price $5.69
Bear Case
Base Case
Bull Case
Monitor RNAZ
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value $2.05
Get notified when the price drops into your buy zone
Current Price $5.69
Intrinsic Value $2.56
Margin of Safety 20% $2.05
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about RNAZ?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is RNAZ valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Transcode Therapeutics Inc.

Explain Valuation
Alternatives to RNAZ

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Transcode Therapeutics Inc

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

RNAZ Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one RNAZ stock?

The intrinsic value for Transcode Therapeutics Inc (RNAZ) under the Base Case is 2.56 USD.

Is RNAZ stock undervalued or overvalued?

Compared with the current market price of 5.69 USD, the stock appears Overvalued by 55% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett